Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary care provider-led cancer survivorship care in the first 5 years following initial cancer treatment: a scoping review of the barriers and solutions to implementation.
Hayes BD, Young HG, Atrchian S, Vis-Dunbar M, Stork MJ, Pandher S, Samper S, McCorquodale S, Loader A, Voss C. Hayes BD, et al. Among authors: atrchian s. J Cancer Surviv. 2024 Apr;18(2):352-365. doi: 10.1007/s11764-022-01268-y. Epub 2022 Nov 15. J Cancer Surviv. 2024. PMID: 36376712 Review.
The microbiome and breast cancer: a review.
Chen J, Douglass J, Prasath V, Neace M, Atrchian S, Manjili MH, Shokouhi S, Habibi M. Chen J, et al. Among authors: atrchian s. Breast Cancer Res Treat. 2019 Dec;178(3):493-496. doi: 10.1007/s10549-019-05407-5. Epub 2019 Aug 27. Breast Cancer Res Treat. 2019. PMID: 31456069 Review.
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Baker S, et al. Among authors: atrchian s. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):856-861. doi: 10.1016/j.ijrobp.2022.06.094. Epub 2022 Jul 13. Int J Radiat Oncol Biol Phys. 2022. PMID: 35840110 Clinical Trial.
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson RA. Baker S, et al. Among authors: atrchian s. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):617-626. doi: 10.1016/j.ijrobp.2022.05.033. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35667528 Clinical Trial.
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S. Olson R, et al. Among authors: atrchian s. JAMA Oncol. 2022 Nov 1;8(11):1644-1650. doi: 10.1001/jamaoncol.2022.4394. JAMA Oncol. 2022. PMID: 36173619 Free PMC article.
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA. Baker S, et al. Among authors: atrchian s. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):849-855. doi: 10.1016/j.ijrobp.2022.08.026. Epub 2022 Oct 24. Int J Radiat Oncol Biol Phys. 2022. PMID: 36302495 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34700549
16 results